PMV Pharmaceuticals to Present Updated Rezatapopt Data at ENA 2026

PRINCETON, N.J., Nov. 04, 2026 /CourierPR/ -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced that updated results from the pivotal Phase 2 portion of the PYNNACLE clinical trial of rezatapopt will be featured in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026). The presentation will include updated data from all PYNNACLE trial cohorts.

Rezatapopt (PC14586) is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. The primary objective of the Phase 1 portion of the clinical trial was to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D) of rezatapopt when administered orally to patients. Safety, tolerability, pharmacokinetics, and effects on biomarkers were also assessed. The Phase 2 portion is a registrational, single arm, expansion basket clinical trial comprising five cohorts (ovarian, lung, breast, and endometrial cancers, and other solid tumors) with the primary objective of evaluating the efficacy of rezatapopt at the RP2D in patients with TP53 Y220C advanced solid tumors, conducted across approximately 70 sites.

PMV Pharma, headquartered in Princeton, New Jersey, was founded by Dr. Arnold Levine, who established the field of p53 biology when he discovered the p53 protein in 1979. PMV Pharma combines unique biological understanding with a pharmaceutical development focus, bringing together leaders in the field to utilize more than four decades of p53 biology.